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Abstract
Introduction: Chondroitin sulfate (CS) and glucosamine sulfate (GS) are symptomatic slow-acting drugs for 
osteoarthritis (OA) widely used in clinic. Despite their widespread use, knowledge of the specific molecular 
mechanisms of their action is limited. The aim of this work is to explore the utility of a pharmacoproteomic approach 
for the identification of specific molecules involved in the pharmacological effect of GS and CS.
Methods: Chondrocytes obtained from three healthy donors were treated with GS 10 mM and/or CS 200 μg/mL, and 
then stimulated with interleukin-1β (IL-1β) 10 ng/mL. Whole cell proteins were isolated 24 hours later and resolved by 
two-dimensional electrophoresis. The gels were stained with SYPRORuby. Modulated proteins were identified by 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF/TOF) mass spectrometry. Real-time PCR and 
Western blot analyses were performed to validate our results.
Results: A total of 31 different proteins were altered by GS or/and CS treatment when compared to control. Regarding 
their predicted biological function, 35% of the proteins modulated by GS are involved in signal transduction pathways, 
15% in redox and stress response, and 25% in protein synthesis and folding processes. Interestingly, CS affects mainly 
energy production (31%) and metabolic pathways (13%), decreasing the expression levels of ten proteins. The 
chaperone GRP78 was found to be remarkably increased by GS alone and in combination with CS, a fact that unveils a 
putative mechanism for the reported anti-inflammatory effect of GS in OA. On the other hand, the antioxidant enzyme 
superoxide dismutase 2 (SOD2) was significantly decreased by both drugs and synergistically by their combination, 
thus suggesting a drug-induced decrease of the oxidative stress caused by IL-1β in chondrocytes.
Conclusions: CS and GS differentially modulate the proteomic profile of human chondrocytes. This 
pharmacoproteomic approach unravels the complex intracellular mechanisms that are modulated by these drugs on 
IL1β-stimulated human articular chondrocytes.
Introduction
Osteoarthritis (OA) is becoming increasingly prevalent
worldwide because of the combination of an aging popu-
lation and growing levels of obesity. Despite the increas-
ing number of OA patients, treatments to manage this
disease are limited to controlling pain and improving
function and quality of life while limiting adverse events
[1]. Effective therapies to regenerate damaged cartilage or
to slow its degeneration have not been developed.
The failure of conventional treatments (analgesics or
non-steroidal anti-inflammatory drugs) to satisfactorily
control OA progression, combined with their frequent
adverse side effects, may explain the increasing use of
such SYSADOA (SYmptomatic Slow-Acting Drugs for
Osteoarthritis) therapies as glucosamine sulfate (GS) and
chondroitin sulfate (CS). Different clinical trials have
proved that GS [2-4] and CS [5,6] are effective in relieving
t h e  s y m p t o m s  o f  O A  [ 7 ] ,  p r o b a b l y  d u e  t o  t h e i r  a n t i -
inflammatory properties. However, although these
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reports were intended to resolve and clarify the clinical
effectiveness of these supplements regarding OA, they
leave doubts among the scientific community and fuel the
controversy [8]. The recently published results of the
Glucosamine/chondroitin Arthritis Intervention Trial
(GAIT) showed that, in the overall group of patients with
osteoarthritis of the knee, GS and CS alone or in combi-
nation did not reduce pain effectively [9]. For a subset of
participants with moderate-to-severe knee pain, how-
ever, GS combined with CS provide statistically signifi-
cant pain relief compared with placebo. One possible
explanation for this discrepancy may be the relative par-
ticipation of inflammatory cytokines in different subpop-
ulations; and it is also hypothesized that the effects of GS
and CS are better realized in patients with more severe
OA, which have greater involvement of interleukin-1beta
(IL-1β) [10].
With the aim to describe more clearly the effects of GS
and CS on cartilage biology and characterize their mech-
anism of action, we performed proteomic analyses of
articular chondrocytes treated with exogenous GS and/or
CS. Most previous studies have evaluated single proteins,
but have not addressed the total chondrocyte proteome.
With the introduction of proteomics, it has become pos-
sible to simultaneously analyze changes in multiple pro-
teins. Proteomics is a powerful technique for
investigating protein expression profiles in biological sys-
tems and their modifications in response to stimuli or
particular physiological or pathophysiological conditions.
It has proven to be a technique of choice for study of
modes of drug action, side-effects, toxicity and resistance,
and is also a valuable approach for the discovery of new
drug targets. These proteomic applications to pharmaco-
logical issues have been dubbed pharmacoproteomics
[11]. Currently, many proteomic studies use two-dimen-
sional electrophoresis (2-DE) to separate proteins [12];
w e  h a v e  r e c e n t l y  u s e d  t h i s  p r o t e o m i c  a p p r o a c h  t o
describe the cellular proteome of normal and osteoar-
thritic human chondrocytes in basal conditions [13,14]
and also under IL-1β stimulation [15].
To more clearly define the effects of GS and CS on car-
tilage biology, we performed proteomic analyses of artic-
ular chondrocytes treated with exogenous GS and/or CS.
Because the treatment efficacy of these compounds
appears to vary with the pathological severity of OA, we
used an in vitro model employing normal human chon-
drocyte cultures stimulated with IL-1β, a proinflamma-
tory cytokine that acts as a mediator to drive the key
pathways associated with OA pathogenesis [16].
Materials and methods
Reagents, chemicals and antibodies
Culture media and fetal calf serum (FCS) were obtained
from Gibco BRL (Paisley, UK). Culture flasks and plates
were purchased from Costar (Cambridge, MA, USA).
Two-dimensional electrophoresis materials (IPG buffer,
strips, and so on) were purchased from GE Healthcare
(Uppsala, Sweden). IL-1β was obtained from R&D Sys-
t e m s  E u r o p e  ( O x f o r d ,  U K ) .  G l u c o s a m i n e  s u l f a t e  a n d
chondroitin sulfate were provided by Bioiberica (Barce-
lona, Spain). Antibody against human SOD2 was
obtained from BD Biosciences (Erembodegem, Belgium),
antibody against α-Tubulin from Sigma-Aldrich (St.
Louis, MO, USA), antibody against human GRP78 and
the correspondent peroxidase-conjugated secondary
antibodies from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Unless indicated, all other chemicals and
enzymes were obtained from Sigma-Aldrich.
Cartilage procurement and processing
Macroscopically normal human knee cartilage from three
adult donors (44, 51 and 62 years old) with no history of
joint disease was provided by the Tissue Bank and the
Autopsy Service at Complejo Hospitalario Universitario
A Coruña. The study was approved by the Ethics Com-
mittee of Galicia, Spain. Cartilage was processed as previ-
ously described [13].
Primary culture of chondrocytes
Chondrocytes were recovered and plated in 162-cm2
flasks in DMEM supplemented with 100 units/mL peni-
cillin, 100 μg/mL streptomycin, 1% glutamine and 10%
FCS. The cells were incubated at 37°C in a humidified gas
mixture containing 5% CO2 balanced with air. At conflu-
ence cells were recovered from culture flasks by trypsini-
zation and seeded onto 100 mm culture plates (2 × 106
per plate) for proteomic studies or six-multiwell plates (5
× 105 per well) for further analysis (RNA/protein extrac-
tion). Chondrocytes were used at Week 2 to 3 in primary
culture (P1), after making them quiescent by incubation
in a medium containing 0.5% FCS for 24 h. Verification of
cell type was carried out by positive immunohistochemis-
try to type II collagen. Finally, cells were cultured in FCS-
free medium containing glucosamine sulfate (10 mM)
and/or chondroitin sulfate (200 μg/mL). Two hours later,
IL-1β was added at 10 ng/ml to the culture medium. All
the experiments were carried out for 24 hours. Cell via-
bility was assessed by trypan blue dye exclusion.
Two-dimensional gel electrophoresis (2-DE)
The 2-DE technique used in this study has been previ-
ously described [13]. Briefly, 200 μg of protein extracts
were applied to 24 cm, pH 3-11 NL, IPG strips by passive
overnight rehydration. The first dimension separation,
isoelectric focusing (IEF), was performed at 20°C in an
IPGphor instrument (GE Healthcare) for a total of 64,000
Vhr. The second dimension separation was run on an
Ettan DALT six system (GE Healthcare) after equilibra-Calamia et al. Arthritis Research & Therapy 2010, 12:R138
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tion of the strips. Electrophoresis followed the technique
of Laemmli [17], with minor modifications. We used 1X
Tris-glycine electrophoresis buffer as the lower buffer
(anode) and 2X Tris-glycine as the upper buffer (cath-
ode).
Protein staining
Gels were fixed and stained overnight with SYPRORuby
(Invitrogen, Carlsbad, CA, USA), according to the manu-
facturer's protocol. After image acquisition and data anal-
ysis, 2-DE gels were stained either with Coomassie
Brilliant Blue (CBB) or silver nitrate according to stan-
dard protocols [18] to allow subsequent mass spectrome-
try (MS) identification.
2-DE image acquisition and data analysis
SYPRO-stained gels were digitized using a CCD camera
(LAS 3000 imaging system, Fuji, Tokyo, Japan) equipped
with a blue (470 nm) excitation source and a 605DF40 fil-
ter. CBB and silver stained gels were digitized with a den-
sitometer (ImageScanner, GE Healthcare). Images from
SYPRO-stained gels were analyzed with the PDQuest
7.3.1 computer software (Bio-Rad, Hercules, CA, USA).
Mass spectrometry (MS) analysis
The gel spots of interest were manually excised and trans-
ferred to microcentrifuge tubes. Samples selected for
analysis were in-gel reduced, alkylated and digested with
trypsin according to the method of Sechi and Chait [19].
The samples were analyzed using the Matrix-assisted
laser desorption/ionization (MALDI)-Time of Flight
(TOF)/TOF mass spectrometer 4800 Proteomics Ana-
lyzer (Applied Biosystems, Framingham, MA, USA) and
4000 Series Explorer™ Software (Applied Biosystems).
Data Explorer version 4.2 (Applied Biosystems) was used
for spectra analyses and generating peak-picking lists. All
mass spectra were internally calibrated using autoprote-
olytic trypsin fragments and externally calibrated using a
standard peptide mixture (Sigma-Aldrich). TOF/TOF
fragmentation spectra were acquired by selecting the 10
most abundant ions of each MALDI-TOF peptide mass
map (excluding trypsin autolytic peptides and other
known background ions).
Database search
The monoisotopic peptide mass fingerprinting data
obtained by MS and the amino acid sequence tag
obtained from each peptide fragmentation in MS/MS
analyses were used to search for protein candidates using
Mascot version 1.9 from Matrix Science [20]. Peak inten-
sity was used to select up to 50 peaks per spot for peptide
mass fingerprinting, and 50 peaks per precursor for MS/
MS identification. Tryptic autolytic fragments, keratin-
and matrix-derived peaks were removed from the dataset
used for the database search. The searches for peptide
m a s s  f i n g e r p r i n t s  a n d  t a n d e m  M S  s p e c t r a  w e r e  p e r -
formed in the Swiss-Prot release 53.0 [21] and TrEMBL
release 37.0 [22] databases. Identifications were accepted
as positive when at least five peptides matched and at
least 20% of the peptide coverage of the theoretical
sequences matched within a mass accuracy of 50 or 25
ppm with internal calibration. Probability scores were
significant at P < 0.01 for all matches. The intracellular
localization of the identified proteins was predicted from
the amino acid sequence using the PSORT II program
[23].
Western blot tests
One-dimensional Western blot analyses were performed
utilizing standard procedures. Briefly, 30 μg of cellular
proteins were loaded and resolved using standard 10%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
The separated proteins were then transferred to polyvi-
nylidene fluoride (PVDF) membranes (Immobilon P, Mil-
lipore Co., Bedford, MA, USA) by electro-blotting and
probed with specific antibodies against SOD2 (1:1000),
GRP78 (1:500), and the housekeeping control α-tubulin
(1:2000). Immunoreactive bands were detected by chemi-
luminescence using corresponding horseradish peroxi-
dase (HRP)-conjugated secondary antibodies and
enhanced chemiluminescence (ECL) detection reagents
(GE Healthcare), then digitized using the LAS 3000
image analyzer. Quantitative changes in band intensities
were evaluated using ImageQuant 5.2 software (GE
Healthcare).
Real-time PCR assays
Total RNA was isolated from chondrocytes (5 × 105 per
well) using Trizol Reagent (Invitrogen, Carlsbad, CA,
USA), following the manufacturer's instructions. cDNA
was synthesized from 1 μg total RNA, using the Tran-
scriptor First Strand cDNA Synthesis Kit (Roche Applied
Science, Indianapolis, IN, USA) in accordance with the
manufacturer's instructions, and analyzed by quantitative
real-time PCR. Quantitative real-time PCR assay was
performed in the LightCycler 480 instrument (Roche
Applied Science) using 96-well plates. Primers for SOD2,
GRP78 and the housekeeping genes, HPRT1 and RPLP0,
were designed using the Universal Probe Library tool
from the Roche website [24]. Primer sequences were as
follows: SOD2 forward, 5'-CTGGACAAACCTCAGC-
CCTA-3'; SOD2 reverse, 5'-TGATGGCTTCCAG-
CAACTC-3'; GRP78 forward, 5'-GGATCATCAA
CGAGCCTACG-3'; GRP78 reverse, 5'-CACCCAGGT-
CAAACACCAG-3'; HPRT1 forward, 5'-TGACCTT-
GATTTATTTTGCATACC-3'; HPRT1 reverse, 5'-
CGAGCAAGACGTTCAGTCCT-3'; RPLP0 forward, 5'-
TCTACAACCCTGAAGTGCTTGAT-3', PRPL0 reverse
5'-CAATCTGCAGACAGACACTGG-3'. The resultsCalamia et al. Arthritis Research & Therapy 2010, 12:R138
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were analyzed using the LightCycler 480 software release
1.5.0 (Roche), which automatically recorded the thresh-
old cycle (Ct). An untreated cell sample (basal) was used
as the calibrator; the fold change for this sample was 1.0.
Target gene Ct values were normalized against HPRT1
and RPLP0. Data were analyzed using the 2-ΔΔCt method
and expressed as fold change of the test sample compared
to the basal condition [25].
Statistical analysis
Each experiment was repeated at least three times. The
statistical significance of the differences between mean
values was determined using a two-tailed t-test. P ≤ 0.05
was considered statistically significant. In the proteomic
analysis, normalization tools and statistical package from
PDQuest software (Bio-Rad) were employed. Where
appropriate, results are expressed as the mean ± standard
error.
Results
To assess the influence of GS and CS on the intracellular
pathways of human particularcz chondrocytes, we com-
pared five different conditions: cells before treatment
(basal), IL-1β-treated cells (control), IL-1β + GS-treated
cells, IL-1β + CS-treated cells and IL-1β + GS + CS-
treated cells. Two-dimensional electrophoresis (2-DE)
gels of each condition were obtained from three healthy
donors (a representative image of them is shown in Figure
1). The 15 digitalized images of these gels were analyzed
using PDQuest analysis software. The program was able
to detect more than 650 protein spots on each gel. The
matched spots (540) were analyzed for their differential
abundance. After data normalization, 48 protein spots
were found to be altered more than 1.5-fold in the GS-
and CS-treated samples (both increased and decreased
compared to control condition), considering only those
with a significance level above 95% by the Student's t-test
(P < 0.05). These spots were excised from the gels and
analyzed by MALDI-TOF and MALDI-TOF/TOF MS.
The resulting protein identifications led to the recogni-
tion of 35 spots corresponding to 31 different proteins
that were modulated by GS- or CS- treatment. Interest-
ingly, some of these proteins, such as heat shock protein
beta-1 (HSPB1) or alpha enolase (ENOA) were present in
more than one spot, indicating that they undergo post-
translational modifications, such as glycosylation or
phosphorylation. Table 1 summarizes the differentially
expressed proteins identified in this proteomic analysis.
Database searches allowed us to classify these 35 pro-
teins according to their subcellular localization and cellu-
lar function. Most of them (52%) were predicted to be
cytoplasmic, while the remaining 48% were either associ-
ated with the cell membrane (20%), extracellular matrix
(8%), or located in subcellular organelles, including the
endoplasmic reticulum (10%), mitochondria (5%) or
nucleus (5%) (Figure 2A). The predicted biological func-
tions for these proteins fell into six major groups: 1)
energy production; 2) signal transduction; 3) protein syn-
thesis and folding; 4) redox process and stress response;
5) cellular organization; and 6) metabolism (Figure 2B).
Proteins modulated by GS treatment
We identified 18 different proteins that were modulated
by GS (Figure 3). Fourteen of these proteins were
increased compared to the control, while six were
decreased. Three of these proteins were found to be posi-
tively modulated only by GS: peroxiredoxin-1 (PRDX1:
redox process), HSPB1 (stress response) and collagen
alpha-1(VI) chain precursor (CO6A1: cell adhesion).
Most of the proteins increased by GS are involved in sig-
nal transduction pathways and in protein synthesis and
folding processes (see Table 1). Interestingly, all the pro-
teins modulated by GS treatment that are related to
energy production were decreased; these include ENOA,
triosephosphate isomerase (TPIS) and the pyruvate
kinase isozymes M1/M2 (KPYM). Other pharmacologi-
cal effects of GS involve the modulation of cellular orga-
nization processes (increase of gelsolin and decrease of
actin) and redox and stress responses (decrease of mito-
chondrial superoxide dismutase).
Proteins modulated by CS treatment
CS modulated 21 different proteins (Figure 3). Only nine
proteins were increased, while 14 were decreased com-
pared to the control condition. Interestingly CS, unlike
GS, seems to affect mainly energy production and meta-
bolic pathways. Proteins related to glycolysis represent
the largest functional group decreased in chondrocytes
treated with CS; these included glyceraldehyde 3-phos-
phate dehydrogenase (G3P), fructose biphosphate aldo-
lase A (ALDOA), phosphoglycerate mutase 1 (PGAM1),
TPIS, phosphoglycerate kinase 1 (PGK1), ATP synthase
subunit alpha, mitochondrial (ATPA) and KPYM. Three
metabolic proteins, AK1C2, GANAB and UDP-glucose 6-
dehydrogenase (UGDH), were also decreased. Similar to
GS treatment, many proteins modulated by CS are
involved in protein synthesis and folding processes. Two
proteins were modified only by CS, neutral alpha-glucosi-
dase AB (GANAB), which is involved in glycan metabo-
lism, and septin-2 (SEPT2), a cell cycle regulator (Figure
3).
Proteins identified as modulated by GS and CS treatment
When administered in combination, GS and CS modi-
fied, in many cases, chondrocyte proteins synergistically.
Overall, this combination modulated 31 spots corre-
sponding to 29 different proteins, 12 of them were
increased and 19 were decreased (Figure 3). These pro-
teins are found in all the functional categories, but mostCalamia et al. Arthritis Research & Therapy 2010, 12:R138
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Table 1: Human articular chondrocyte proteins modified by treatment with interleukin-1β (IL-1β) plus glucosamine and/
or chondroitin sulfate
Spot n° Protein name Acc. n°§ GS‡ CS‡ GS+CS‡ Loc.** Mr/pI§§ Cellular role
1 PDIA1 Protein disulfide-isomerase 
precursor
P07237 6.54 5.60 11.24 ER, CM 57.1/4.76 Protein folding
2 ANXA5 Annexin A5 P08758 1.97 1.30 1.52 C 35.9/4.94 Signal transduction
3 GDIR Rho GDP-dissociation inhibitor 1 P52565 2.62 1.03 2.51 C 23.2/5.03 Signal transduction
4 GRP78 78 kDa glucose-regulated protein 
precursor
P11021 8.08 1.19 14.15 ER 72.3/5.07 Protein folding
5 CO6A1 Collagen alpha-1(VI) chain 
precursor
P12109 4.14 -1.96 -1.5 EXC 108.5/5.26 Cell adhesion
6 ACTB Actin, cytoplasmic 1 P60709 -3.7 -1.41 -1.89 C, CK 41.7/5.29 Cell motion
7 HSP7C Heat shock cognate 71 kDa protein P11142 7.20 3.90 5.46 C 70.9/5.37 Protein folding
8 GSTP1 Glutathione S-transferase P P09211 -1.2 -1.54 -1.49 C 23.3/5.43 Detoxification
9 HSPB1 Heat shock protein beta-1 P04792 -1.33 -1.35 -1.75 C, N 22.8/5.98 Stress response
10 PDIA3 Protein disulfide-isomerase A3 
precursor
P30101 9.59 9.74 12.50 ER 56.8/5.98 Protein folding
11 PDIA3 Protein disulfide-isomerase A3 
precursor
P30101 10.24 5.29 7.13 ER 56.8/5.98 Protein folding
12 GELS Gelsolin P06396 5.93 3.12 3.98 C, CK 85.7/5.90 Actin depolymerizer
13 HSPB1 Heat shock protein beta-1 P04792 1.94 -1.25 1.26 C, N 22.8/5.98 Stress response
14 GANAB Neutral alpha-glucosidase AB Q14697 1.15 -1.56 -1.09 ER, G 106.9/5.74 CH Metabolism
15 ANXA1 Annexin A1 P04083 1.56 1.72 1.90 C, N, CM 38.7/6.57 Signal transduction
16 SEPT2 Septin-2 Q15019 1.08 -1.51 -1.35 N 41.5/6.15 Cell cycle/division
17 ENOA Alpha-enolase P06733 1.04 1.91 1.89 C, CM 47.2/7.01 Glycolysis
18 EF1G Elongation factor 1-gamma P26641 -1.28 -1.85 -1.92 C 50.2/6.25 Protein synthesis
19 TCPG T-complex protein 1 subunit 
gamma
P49368 -1.39 -1.54 -1.96 C 60.5/6.10 Protein folding
20 DPYL2 Dihydropyrimidinase-related 
protein 2
Q16555 -1.12 -1.45 -1.79 C 62.3/5.95 Metabolism
21 SODM Superoxide dismutase 
mitochondrial
P04179 -2.5 -1.3 -4.35 MIT 24.7/8.35 Redox
22 PGAM1 Phosphoglycerate mutase 1 P18669 -1.33 -1.23 -1.54 C 28.8/6.67 Glycolysis
23 TPIS Triosephosphate isomerase P60174 -1.69 -1.49* -1.72 C 26.7/6.45 Glycolysis
24 ANXA2 Annexin A2 P07355 3.44 6.80 5.12 EXC, CM 38.6/7.57 Trafficking
25 AK1C2 Aldo-keto reductase family 1 
member C2
P52895 -2 -2.13 -3.22 C 36.7/7.13 Metabolism
26 ENOA Alpha-enolase P06733 -1.96 -1.37 -1.92 C, CM 47.2/7.01 Glycolysis
27 UGDH UDP-glucose 6-dehydrogenase O60701 -1.16 -2.08 -1.85 C 55.0/6.73 Metabolism
28 ANXA2 Annexin A2 P07355 2.69 3.06 2.82 EXC, CM 38.6/7.57 Trafficking
29 PGK1 Phosphoglycerate kinase 1 P00558 -1.14 -2.33 -2.32 C 44.6/8.30 Glycolysis
30 ATPA ATP synthase subunit alpha, 
mitochondrial
P25705 -1.43 -2.17 -2.22 MIT 59.8/9.16 Respiration
31 KPYM Pyruvate kinase isozymes M1/M2 P14618 -1.59 -2.44 -2.5 C 57.9/7.96 Glycolysis
32 TAGL2 Transgelin-2 P37802 1.31 -1.09 -1.43* CK, CM 22.4/8.41 Structural
33 PRDX1 Peroxiredoxin-1 Q06830 1.67 -1.12 -1.09 C 22.1/8.27 RedoxCalamia et al. Arthritis Research & Therapy 2010, 12:R138
http://arthritis-research.com/content/12/4/R138
Page 6 of 12
are involved in energy production, protein synthesis and
folding. Four of these proteins are modulated only by the
combined treatment: a specific isoform of HSPB1, dihy-
dropyrimidinase-related protein 2 (DPYL2), phospho-
glycerate mutase 1 (PGAM1), and transgelin-2 (TAGL2).
Verification of the modulation of GRP78 and SOD2
The results obtained by our pharmacoproteomic analysis
need to be validated for differences in protein expression
profiles before the biological roles of the modulated pro-
teins are extensively studied. We selected two proteins,
34 G3P Glyceraldehyde-3-phosphate 
dehydrogenase
P04406 -1.27 -2.04 -2.63 C, CM 36.1/8.57 Glycolysis
35 ALDOA Fructose-bisphosphate aldolase A P04075 -1.22 -1.79 -1.89 C 39.4/8.30 Glycolysis
§ Protein accession number according to SwissProt and TrEMBL databases.
‡ Average volume ratio vs IL-1β, quantified by PDQuest 7.3.1. software. * Protein altered less than 1.5-fold but with a significance level above 95% 
by the Student's t-test (p< 0.05).
** Predicted subcellular localization according to PSORTII program. 
§§ Theoretical molecular weight (Mr) and isoelectric point (pI) according to protein sequence and Swiss-2DPAGE database.
C, cytoplasm; CK, cytoskeleton; CM, cell membrane;  ER, endoplasmic reticulum; EXC, extracellular matrix; G, Golgi apparatus; MIT, mitochondria; 
N, nucleus.
Table 1: Human articular chondrocyte proteins modified by treatment with interleukin-1β (IL-1β) plus glucosamine and/
or chondroitin sulfate (Continued)
Figure 1 Representative two-dimensional electrophoresis (2-DE) map of human articular chondrocyte proteins obtained in this work. Pro-
teins were resolved in the 3 to 11 (non linear) pH range on the first dimension, and on 10% T gels on the second dimension. The 35 mapped and 
identified spots are annotated by numbers according to Table 1.Calamia et al. Arthritis Research & Therapy 2010, 12:R138
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possibly involved in the OA process, on which to perform
additional studies in order to verify their altered expres-
sion in GS and CS-treated chondrocytes: GRP78 and
SOD2.
GRP78 was previously reported by our group to be
related to OA pathogenesis [14]. We performed orthogo-
nal studies to verify the eight-fold increase of this protein
compared to the IL-1β-treated control group observed in
the proteomic analysis. Real-time PCR assays demon-
strated the GS-dependent upregulation of GRP78 gene
expression, showing remarkable increases of almost 30-
f o l d  i n  G S-t r e a t e d  c h o n d r o cyt e s  ( P  < 0.05, n = 6, age
range: 55 to 63 years), and even slightly higher with com-
bined GS and CS treatment (Figure 4A). These results
were confirmed at the protein level by Western blot anal-
ysis in four independent experiments. Densitometric
analysis of the band intensities revealed an increase of
GRP78 protein in GS- and GS + CS-treated samples that
averaged 1.72-fold and 1.75-fold greater than control (P <
0.05) (Figure 4B).
Mitochondrial SOD2, a protein previously reported to
be related to the OA disease process [26], was decreased
by GS and GS+CS treatment in our proteomic screening.
To validate our data, real-time PCR analyses were carried
out on RNA samples isolated from four independent
experiments (Figure 5A). The results showed a significant
(P < 0.001) up-regulation of SOD2 gene expression in IL-
1β-stimulated cells, with an increase of 44-fold, and a
subsequent 70% decrease in GS- and GS+ CS-treated
cells. We also carried out Western blot analyses to exam-
ine SOD2 modulation at the protein level. A decrease in
SOD2 protein levels was evident in all donors (n = 7, age
range: 51 to 72 years old). Figure 5B shows data from the
densitometric analysis of the blots, revealing a two-fold
increase in IL-1β-stimulated cells with subsequent 75%
decrease of SOD2 in GS + CS-treated cells (P < 0.05).
Figure 2 Subcellular localization (A) and functional distribution (B) of the GS- and/or CS-modulated proteins identified by proteomics. Da-
tabase searches were used to classify these 35 proteins according to their subcellular localization and cellular function. Based on these characteristics, 
the proteins were assigned into six groups.
Figure 3 Proteins modulated similarly and differently by GS-, CS- 
and GS+CS-treatment in IL-1β-treated human articular chondro-
cytes. Proteins in the yellow circle are modulated by GS, proteins in the 
green circle are modulated by CS, and proteins in the white circle are 
modulated by the combination treatment. Upregulated proteins are 
indicated in red and downregulated proteins are in black (*two differ-
ent isoforms; #the same isoform).Calamia et al. Arthritis Research & Therapy 2010, 12:R138
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Discussion
In the present work, we examined the utility of a pharma-
coproteomic approach for analyzing the putative intracel-
lular targets of glucosamine (GS) and chondroitin
sulphate (CS) in cartilage cells. Using proteomic tech-
niques, we studied the influence of these compounds,
both alone and in combination, on the molecular biology
of chondrocytes challenged with the proinflammatory
cytokine IL-1β.
The conditions used in this study represent supraphysi-
ological levels of both drugs and cytokine. These concen-
trations, however, are included in the range of in vitro
concentrations used by other laboratories, thus facilitat-
ing the comparison with other studies [27,28]. In our
work, we chose them according to the bibliography,
where a very wide range of both glucosamine and chon-
droitin sulfate have been used on different cell types and
Figure 4 The 78 kDa glucose-regulated protein precursor 
(GRP78) is increased by GS alone and in combination with CS. A. 
Overexpression values of GRP78 determined by real-time polymerase 
chain reaction (PCR) analysis of cultured human articular chondrocytes 
treated with interleukin-1β (IL-1β) plus GS and/or CS (n = 6, P < 0.05*). 
B. Western blot analysis of GRP78 protein levels in treated chondro-
cytes. A representative blot is shown, along with the numeric data ob-
tained by densitometry analysis of the blots (n = 4, P < 0.05*).
Figure 5 Mitochondrial superoxide dismutase (SOD2) is de-
creased by GS alone and in combination with CS. A. Underexpres-
sion values of SOD2 determined by real-time polymerase chain 
reaction (PCR) analysis on cultured human articular chondrocytes 
treated with interleukin-1β (IL-1β) plus GS and/or CS (n = 4, P < 0.05*). 
B. Western blot analysis of SOD2 protein levels in treated chondro-
cytes. A representative blot is shown, along with the numeric data ob-
tained by densitometry analysis of the blots (n = 7, P < 0.05*).Calamia et al. Arthritis Research & Therapy 2010, 12:R138
http://arthritis-research.com/content/12/4/R138
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tissues [29,30]. We tested different concentrations of both
drugs in the standardization step of the proteomic analy-
sis (CS from 10 to 200 μg/ml and GS from 1 to 10 mM),
and selected the highest concentrations in order to better
unravel the molecular mechanisms that are modulated by
these compounds. Moreover, in the case of glucosamine
it is important to emphasize that its pharmacokinetic is
modulated by the levels of glucose in the culture medium,
as it utilizes glucose transporters to be taken up by the
cells [31,32]. Since our cells are grown under high levels
of glucose (DMEM, containing 25 mmol/l glucose), it is
necessary to use high concentrations of glucosamine in
order to appreciate its effect in the presence of high glu-
cose. The molecular mechanisms driven with these high
amounts of both drugs might not be comparable to their
classical oral administration, but they can mimic a direct
delivery into the joint. In this sense, it has been recently
proposed that intra-articular administration of CS may
provide an immediate contact with the synoviocytes and
chondrocytes, as is the case in cellular culture models
[33]. Furthermore, a recent study performed on cartilage
explants shows how cyclic preloading significantly
increased tissue PG content and matrix modulus when
they are directly supplemented with high concentrations
of the combination of GS and CS (500 μg/ml and 250 μg/
ml, respectively), resulting in a reduction of matrix dam-
age and cell death following an acute overload [34].
All the mentioned limitations are inherent to in vitro
studies, and also highlight the screening utility of pro-
teomic approaches. Given the high complexity of these
kinds of studies (and specifically the present one, in
which five different conditions are evaluated), it is essen-
tial to be reminded how these approaches aim to screen
for differences between the conditions that are being
compared, opening the door for subsequent more
exhaustive verification studies of some of these changes
(which would allow both the inclusion of more samples to
be analyzed and the performance of time-course or dose-
response experiments). As a proof of the act, in this work
(and based on their previously described relationship
with OA pathogenesis) we selected one protein that was
increased (GRP78) by the drug treatment and one that
was decreased (SOD2), and performed orthogonal stud-
ies on them to verify their alteration.
Despite their limitations, several in vitro studies have
previously shown how CS and GS could moderate some
aspects of the deleterious response of chondrocytes to
stimulation with IL-1β. In chondrocyte cultures, GS and
CS diminish the IL-1β-mediated increase of metallopro-
teases, [35,36] the expression of phospholipase A2 [37,38]
and cyclooxygenase-2, [39] and the concentrations of
prostaglandin E2 [40]. They also reduce the concentration
of pro-inflammatory cytokines, such as tumor necrosis
factor-α (TNF-α) and IL-1β, in joints, [41] and systemic
and joint concentrations of nitric oxide [42] and reactive
oxygen species (ROS) [43]. All these studies showed simi-
lar results for both molecules, mainly related to their
anti-inflammatory effect, while the results obtained by
our pharmacoproteomic approach highlight the different
molecular mechanisms affected by GS or CS. It is essen-
tial to point out that our study has been performed with
chondrocytic intracellular extracts. In this context, it is
difficult to identify proteins that are known to be secreted
by the chondrocytes, such as metalloproteinases, cytok-
ines or aggrecanases, which have been the focus of a
recent mRNA-based analysis [44], or hyaluronan syn-
thases, which have been newly found to be increased by
CS in synoviocytes [45]. All these were also described to
be modulated by GS in a previous transcriptomic study
[10]. However, detection of this type of proteins in intrac-
ellular fractions by shotgun proteomics is not easily
achievable because they are mainly delivered to the extra-
cellular space after their synthesis, being those small
amounts that are retained inside the cells masked by
other typical cytoplasmic proteins which are more abun-
dant [13]. Given the high dynamic range of proteins in
b i o l o g i c a l  s y s t e m s ,  t h i s  p r o b l e m  i s  i n h e r e n t  t o  g l o b a l
screening proteomic experiments, and is only solvable
employing hypothesis-driven proteomics strategies (tar-
geted proteomics).
As mentioned before, this study is focused on the inves-
tigation of the intracellular mechanisms modulated by CS
and GS, which are the background for ulterior putative
changes of ECM turnover. In our work, 25% of the pro-
teins modulated by GS are involved in signal transduction
pathways, 15% in redox and stress response, and 25% in
protein synthesis and folding processes, whereas CS
affects mainly energy production (31%) and metabolic
pathways (13%) by decreasing the expression levels of 10
proteins (Figure 1B). Bioinformatic analysis using Path-
way Studio 6.1 software (Ariadne Genomics, Rockville,
MD, USA) enabled the characterization of the biological
association networks related to these differentially
expressed chondrocytic proteins. A simplified picture of
their interactions is showed in Figure 6. Using this analy-
sis, we identified the biochemical pathways that may be
altered when chondrocytes are treated with GS and CS.
Most of the proteins modulated by GS belong to the
complex homeostatic signalling pathway known as the
unfolded protein response (UPR). The UPR system is
involved in balancing the load of newly synthesized pro-
teins with the capacity of the ER to facilitate their matura-
tion. Dysfunction of the UPR plays an important role in
certain diseases, particularly those involving tissues like
cartilage that are dedicated to extracellular protein syn-
thesis. The effect of GS on molecular chaperones and the
role of protein disulfide isomerases (PDIs) in the matura-
tion of proteins related with cartilage ECM structure haveCalamia et al. Arthritis Research & Therapy 2010, 12:R138
http://arthritis-research.com/content/12/4/R138
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been described [46]. PDIA3 (GRP58) is a protein on the
ER that interacts with the lectin chaperones, calreticulin
and calnexin, to modulate the folding of newly synthe-
sized glycoproteins [47], whereas PDIA1 (prolyl 4-
hydroxylase subunit beta) constitutes a structural subunit
of prolyl 4-hydroxylase, an enzyme that is essential for
procollagen maturation [48]. The marked GS-mediated
increase of these proteins in chondrocytes points to an
elevation in ECM protein synthesis, which might be also
hypothesized by the detected increase in Type IV Colla-
gen (COL6A1, essential for chondrocyte anchoring to the
pericellular matrix [49]) synthesis caused by GS.
Finally, GS remarkably increases another UPR-related
protein, GRP78 (BiP), a fact that we confirmed both at
transcript and protein levels. This protein is localized in
the ER, and has been previously identified as an RA
autoantigen [50], which was subsequently characterized
by its anti-inflammatory properties through the stimula-
tion of an anti-inflammatory gene program from human
monocytes and the development of T-cells that secrete
regulatory cytokines such as IL-10 and IL-4 [51]. In a pre-
vious work, we found an increase of this protein in OA
chondrocytes, which might be a consequence of height-
ened cellular stress [14]. A number of previous reports
have described the positive modulation of GS on ER pro-
teins, including GRP78 expression [52], but this is the
first time that such modulation was found to arise from
GS treatment in chondrocytes; thus interestingly suggest-
ing an specific mechanism of action for the putative anti-
inflammatory effect of GS in OA.
On the other hand, most proteins modulated by CS are
proteins related to metabolism and energy production. It
is remarkable that all except one (an enolase isoform)
were decreased. In this group, we identified seven out of
the 10 enzymes that directly participate in the glycolysis
pathway (aldolase, triose phosphate isomerase, glyceral-
dehyde phosphate dehydrogenase, phosphoglycerate
kinase, phosphoglyceromutase, enolase and pyruvate
kinase). This suggests that, while IL-1β treatment tends
to elevate glycolytic energy production ([15] and our
observations), it is then lowered by CS (which reduces
five of these enzymes) and by the combination of both
drugs (which reduces all seven glycolytic enzymes). The
decrease of Neutral alpha-glucosidase AB (or glucosidase
II, GANAB), only caused by CS alone (Figure 2), and two
other metabolism-related proteins (AK1C2 and UGDH),
points also to a reduction of cellular metabolism.
GANAB is an ER-enzyme that has profound effects on
the early events of glycoprotein metabolism, and has been
recently proposed as biomarker for detecting mild human
knee osteoarthritis [53].
Interestingly, only four proteins were found to be mod-
ulated by GS and CS combination but not by either of the
drugs alone, whereas we observed a quantitative syner-
gistic effect of the combination in more than a half (55%)
of the altered proteins (Table 1). One of the proteins
whose decrease by both drugs alone was significant and
furthermore powered by their combination is the redox-
related protein SOD2. This protein, the mitochondrial
superoxide dismutase, has substantial relevance in stress
oxidative pathways and in cytokine-related diseases, such
as OA [54]. We found SOD2 to be upregulated by IL-1β
([15] and our observations), and downregulated by GS
and CS treatment, both at the transcriptional and protein
levels (Real Time-PCR and Western blotting). Supporting
our findings, other authors have recently reported the
role of GS in counteracting the IL-1β-mediated increase
of inducible nitric oxide synthase (iNOS) and the
decrease of heme oxygenase, and indicated that the influ-
ence of GS and CS on oxidative stress is a possible mech-
anism of action for its protective effect on chondrocytes
[55].
Conclusions
Taking into account the limitations of an in vitro study,
our findings provide evidence for the usefulness of pro-
teomics techniques for pharmacological analyses. The
potential application of this approach is to identify effi-
cacy markers for monitoring different OA treatments. In
this study, a number of target proteins of GS and CS have
Figure 6 Pathways and networks related to chondrocyte proteins 
identified by proteomics as altered by GS and/or CS. Pathway Stu-
dio software was used to map the identified proteins into character-
ized human pathways and networks that associate proteins based on 
known protein-protein interactions, mRNA expression studies and oth-
er previously described biochemical interactions. Abbreviations are 
shown as in Table 1. Most of the proteins modulated by GS belong to 
the unfolded protein response (UPR) system, while CS seems to affect 
mainly energy production (glycolysis) and metabolic pathways.Calamia et al. Arthritis Research & Therapy 2010, 12:R138
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been described, pointing out the wide-ranging effects of
these drugs on fundamental aspects of chondrocyte
metabolism, but also their alternative mechanisms of
action in a system model of OA.
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